Uri Aharon - Redhill Biopharma Chief Accounting Officer
| RDHL Stock | USD 0.43 0.01 2.27% |
Executive
Mr. Uri Hananel Aharon serves as Chief Accounting Officer at Redhill Biopharma Ltd, effective since 2012. His work experience includes the following roles Team Manager at Ernst Young Israel and Accounting Intern at Ziv Haft, BDO . He holds a Bachelors degree in Accounting and Economics from The Hebrew University of Jerusalem and a MBA degree, majoring in Business Taxation, from the College of Management Academic Studies, Rishon LeZion. since 2011.
| Age | 35 |
| Tenure | 13 years |
| Professional Marks | MBA |
| Address | 21 Ha?arba?a Street, Tel Aviv, Israel, 6473921 |
| Phone | 972 3 541 3131 |
| Web | https://www.redhillbio.com |
Redhill Biopharma Management Efficiency
The company has return on total asset (ROA) of (0.1571) % which means that it has lost $0.1571 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (8.8429) %, meaning that it created substantial loss on money invested by shareholders. Redhill Biopharma's management efficiency ratios could be used to measure how well Redhill Biopharma manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Redhill Biopharma's Return On Tangible Assets are quite stable compared to the past year. Return On Assets is expected to rise to 1.09 this year, although the value of Return On Capital Employed is projected to rise to (7.83). At this time, Redhill Biopharma's Other Assets are quite stable compared to the past year. Return On Tangible Assets is expected to rise to 1.44 this year, although the value of Other Current Assets will most likely fall to about 757.2 K.Similar Executives
| Found 6 records | EXECUTIVE Age | ||
| Assad Kazeminy | Lucy Scientific Discovery | 73 | |
| Jackie Klecker | Lifecore Biomedical | N/A | |
| Darren Hieber | Lifecore Biomedical | N/A | |
| Kara Morley | Lifecore Biomedical | N/A | |
| Steve Laninga | Lifecore Biomedical | N/A | |
| Matt Augustson | Lifecore Biomedical | N/A | |
Management Performance
| Return On Equity | -8.84 | ||||
| Return On Asset | -0.16 |
Redhill Biopharma Leadership Team
Elected by the shareholders, the Redhill Biopharma's board of directors comprises two types of representatives: Redhill Biopharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Redhill. The board's role is to monitor Redhill Biopharma's management team and ensure that shareholders' interests are well served. Redhill Biopharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Redhill Biopharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Patricia Anderson, Vice President - Regulatory Affairs | ||
| Micha Chorin, CFO | ||
| Ofer Tsimchi, Director | ||
| Razi Ingber, Chief Officer | ||
| Patrick Mclean, Product Manager | ||
| Aida Bibliowicz, Vice President - Clinical Affairs Europe | ||
| Ori Shilo, Co-Founder and Deputy CEO of Fin. and Operations | ||
| Shmuel Cabilly, Director | ||
| Dror BenAsher, Chairman of the Board, CEO | ||
| Rob Jackson, VP Marketing | ||
| Kenneth Reed, Director | ||
| Elkan Gamzu, Product Manager | ||
| Adi Frish, Sr. VP of Bus. Devel. and Licensing | ||
| Guy Goldberg, Chief Business Officer | ||
| Alexandra Okmian, Senior Manager | ||
| Guy JD, Chief Officer | ||
| Reza Fathi, Senior Development | ||
| Tom Lang, Vice President - Regulatory & Clinical Affairs | ||
| Clara Fehrmann, Product Manager | ||
| Kristin Comer, G VP | ||
| Pascal Weerts, Director - Corporate and Legal Affairs | ||
| Valerie Graceffa, VP Sales | ||
| Eric Swenden, Director | ||
| Dan Suesskind, Director | ||
| Gilead Raday, Senior Vice President - Product and Corporate Development | ||
| Rick Scruggs, President Officer | ||
| Terry Plasse, Medical Director | ||
| Danielle Abramson, Director - Intellectual Property & Research | ||
| Micha BenChorin, Chief Officer | ||
| Patricia RAC, Senior Affairs | ||
| MSc MPhil, Chief Officer | ||
| Uri Aharon, Chief Accounting Officer | ||
| FACP MD, Chief Officer | ||
| Shani Maurice, Vice President - Business Development & Communications | ||
| Patricia Bandeira, Product Manager - Oncology | ||
| Ira Kalfus, Medical Director | ||
| Nurit Benjamini, External Director |
Redhill Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Redhill Biopharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -8.84 | ||||
| Return On Asset | -0.16 | ||||
| Profit Margin | 3.66 % | ||||
| Operating Margin | (10.61) % | ||||
| Current Valuation | 3.36 B | ||||
| Shares Outstanding | 31.87 M | ||||
| Shares Owned By Institutions | 6.24 % | ||||
| Number Of Shares Shorted | 906.88 K | ||||
| Price To Earning | (3.67) X | ||||
| Price To Book | 6.55 X |
Currently Active Assets on Macroaxis
When determining whether Redhill Biopharma is a strong investment it is important to analyze Redhill Biopharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Redhill Biopharma's future performance. For an informed investment choice regarding Redhill Stock, refer to the following important reports:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Redhill Biopharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate. For more information on how to buy Redhill Stock please use our How to buy in Redhill Stock guide.Note that the Redhill Biopharma information on this page should be used as a complementary analysis to other Redhill Biopharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Complementary Tools for Redhill Stock analysis
When running Redhill Biopharma's price analysis, check to measure Redhill Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Redhill Biopharma is operating at the current time. Most of Redhill Biopharma's value examination focuses on studying past and present price action to predict the probability of Redhill Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Redhill Biopharma's price. Additionally, you may evaluate how the addition of Redhill Biopharma to your portfolios can decrease your overall portfolio volatility.
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins |
Is Redhill Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Redhill Biopharma. If investors know Redhill will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Redhill Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 4 | Revenue Per Share 1.008 | Quarterly Revenue Growth (0.96) | Return On Assets (0.16) | Return On Equity (8.84) |
The market value of Redhill Biopharma is measured differently than its book value, which is the value of Redhill that is recorded on the company's balance sheet. Investors also form their own opinion of Redhill Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Redhill Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Redhill Biopharma's market value can be influenced by many factors that don't directly affect Redhill Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Redhill Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Redhill Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Redhill Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.